Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 17, 2026, 5:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 54 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Elotuzumab Clear all
Active, not recruiting Phase 3 Interventional

A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

NCT06208150
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Talquetamab, Pomalidomide, Teclistamab, Elotuzumab, Dexamethasone, Bortezomib
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
838 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
49
States / cities
Clovis, California • Santa Monica, California • New Haven, Connecticut + 41 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 17, 2026, 5:48 AM EDT
Terminated Phase 2 Interventional

Combination Study for High Risk Multiple Myeloma Patients

NCT03104270
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Pomalidomide, Carfilzomib, Dexamethasone
Drug
Lead sponsor
Oncotherapeutics
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
6
States / cities
Encinitas, California • Fountain Valley, California • Monterey, California + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2022 · Synced Oct 17, 2026, 5:48 AM EDT
Active, not recruiting Phase 2 Interventional

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

NCT04517851
View directory record Official record
Conditions
Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis
Interventions
Elotuzumab, Questionnaire Administration
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Oct 17, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

Phase III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Newly Diagnosed, Previously Untreated Multiple Myeloma

NCT01335399
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Lenalidomide, Dexamethasone, Elotuzumab (BMS-901608; HuLuc63)
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2021
U.S. locations
88
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 70 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2022 · Synced Oct 17, 2026, 5:48 AM EDT
Terminated Phase 3 Interventional Results available

PH III Study of Lenalidomide and Dexamethasone With or Without Elotuzumab to Treat Previously Untreated Multiple Myeloma (ELO 1 Substudy)

NCT01891643
View directory record Official record
Conditions
Newly Diagnosed, Previously Untreated Multiple Myeloma
Interventions
Lenalidomide, Dexamethasone, Elotuzumab
Drug · Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
9
States / cities
San Francisco, California • Hollywood, Florida • Peoria, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Oct 17, 2026, 5:48 AM EDT
Terminated Phase 2 Interventional Results available

Elotuzumab Plus Lenalidomide (Elo/Rev) for Serologic Relapse/Progression While on Lenalidomide

NCT03411031
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 29, 2023 · Synced Oct 17, 2026, 5:48 AM EDT
Withdrawn Phase 2 Interventional

An Exploratory Study to Evaluate the Combination of Elotuzumab and Nivolumab With and Without Pomalidomide in Relapsed Refractory Multiple Myeloma

NCT03227432
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Dexamethasone, Pomalidomide, Elotuzumab, Nivolumab
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
3
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 17, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Results available

E-PRISM: Phase II Trial of Elotuzumab Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma

NCT02279394
View directory record Official record
Conditions
Smoldering Myeloma, Smoldering Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
9
States / cities
Denver, Colorado • Hartford, Connecticut • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 17, 2026, 5:48 AM EDT
Recruiting Phase 3 Interventional

A Trial to Learn How Well Linvoseltamab Works Compared to the Combination of Elotuzumab, Pomalidomide and Dexamethasone for Adult Participants With Relapsed/Refractory Multiple Myeloma

NCT05730036
View directory record Official record
Conditions
Relapsed Refractory Multiple Myeloma (RRMM)
Interventions
Linvoseltamab, Elotuzumab, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2033
U.S. locations
10
States / cities
Los Angeles, California • Gainesville, Florida • Lexington, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 17, 2026, 5:48 AM EDT
Withdrawn Phase 2 Interventional

2015-10: Expanded Natural Killer Cells and Elotuzumab for High-Risk Myeloma Post- Autologous Stem Cell Transplant (ASCT)

NCT03003728
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Melphalan, Autologous Stem Cell Transplant (ASCT), Expanded Natural Killer (ENK) Cells, ALT-803
Drug · Procedure · Biological
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2020 · Synced Oct 17, 2026, 5:48 AM EDT
Completed Phase 1 Interventional

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

NCT02252263
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lirilumab, Urelumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
6
States / cities
Little Rock, Arkansas • Baltimore, Maryland • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2017 · Synced Oct 17, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Results available

Study of Safety of Elotuzumab Administered Over Approximately 60 Minutes in Combination With Lenalidomide and Dexamethasone for Newly Diagnosed or Relapsed/Refractory Multiple Myeloma Patients

NCT02159365
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
29
States / cities
Tucson, Arizona • Fayetteville, Arkansas • Bakersfield, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jul 16, 2019 · Synced Oct 17, 2026, 5:48 AM EDT
Completed Phase 3 Interventional Results available

An Investigational Immuno-therapy Study of Nivolumab, Pomalidomide and Dexamethasone Combinations in Patients With Multiple Myeloma

NCT02726581
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Nivolumab, Elotuzumab, Pomalidomide, Dexamethasone
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
72
States / cities
Birmingham, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 65 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2023 · Synced Oct 17, 2026, 5:48 AM EDT
Active, not recruiting Phase 3 Interventional

Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

NCT06158841
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Etentamig, Carfilzomib, Pomalidomide, Elotuzumab, Selinexor, Bortezomib, Dexamethasone
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
46
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 37 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 17, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Results available

Elotuzumab, Lenalidomide and Dexamethasone in Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma Patients

NCT02843074
View directory record Official record
Conditions
Multiple Myeloma
Interventions
elotuzumab, Lenalidomide, Dexamethasone, autologous stem cell transplantation
Drug · Procedure
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
6
States / cities
Denver, Colorado • Bethesda, Maryland • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2023 · Synced Oct 17, 2026, 5:48 AM EDT
Terminated Phase 1 Interventional

A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.

NCT00726869
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab (HuLuc63)
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2012 · Synced Oct 17, 2026, 5:48 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

NCT02718833
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Pomalidomide, Bortezomib, Dexamethasone
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
6
States / cities
Boston, Massachusetts • Danvers, Massachusetts • Newton, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 17, 2026, 5:48 AM EDT
Recruiting Phase 3 Interventional

Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma

NCT07772024
View directory record Official record
Conditions
Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Interventions
InoPd, Investigator's choice of SAT
Drug
Lead sponsor
CellCentric Ltd.
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 17, 2026, 5:48 AM EDT
Active, not recruiting Phase 1 Interventional

Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies

NCT05981209
View directory record Official record
Conditions
Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Dexamethasone, Echocardiography, Elotuzumab, Magnetic Resonance Imaging, Mezigdomide, X-Ray Imaging
Procedure · Drug · Biological
Lead sponsor
Abdullah Khan
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated May 13, 2026 · Synced Oct 17, 2026, 5:48 AM EDT
Terminated Phase 2 Interventional Results available

Elotuzumab in Immunoglobulin G4-Related Disease (IgG4-RD)

NCT04918147
View directory record Official record
Conditions
IgG4 Related Disease, IgG4-RD
Interventions
elotuzumab, placebo for elotuzumab, methylprednisolone, diphenhydramine, acetaminophen, famotidine, prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 70 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2026 · Synced Oct 17, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Results available

A Study of Elotuzumab in Combination With Pomalidomide and Low Dose Dexamethasone and Elotuzumab in Combination With Nivolumab in Patients With Multiple Myeloma Relapsed or Refractory to Prior Treatment With Lenalidomide.

NCT02612779
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Pomalidomide, Dexamethasone, Nivolumab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
22
States / cities
Mobile, Alabama • Santa Barbara, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 17, 2026, 5:48 AM EDT
Completed Phase 2 Interventional Results available

Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple Myeloma

NCT03713294
View directory record Official record
Conditions
Refractory Plasma Cell Myeloma
Interventions
Dexamethasone, Elotuzumab, Pomalidomide
Drug · Biological
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 17, 2026, 5:48 AM EDT
Completed Phase 1 Interventional

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

NCT02655458
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab, Lenalidomide, autologous PBMC reconstitution, ASCT
Drug · Other
Lead sponsor
Hearn Jay Cho
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 18, 2017 · Synced Oct 17, 2026, 5:48 AM EDT
No Longer Available No phase listed Expanded access

Expanded Access Single Named Patient Program With Elotuzumab (BMS-901608) for the Treatment of Patient R-A With Relapsed/Refractory Multiple Myeloma

NCT02541643
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Elotuzumab
Drug
Lead sponsor
Sundar Jagannath
Other
Eligibility
18 Years and older
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 4, 2015 · Synced Oct 17, 2026, 5:48 AM EDT